Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates LNCB74, a B7-H4 targeted antibody-drug conjugate, as monotherapy for adults with advanced, unresectable, or metastatic solid tumors that express B7-H4, aiming to evaluate its safety, tolerability, and efficacy. Participants must have measurable disease, an ECOG performance status of 0-1, and adequate organ function.

ClinicalTrials.gov ID: NCT06774963

Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic EGFR-mutant non-small cell lung cancer who have progressed on third-generation EGFR-TKIs, exploring the safety and efficacy of BG-60366, an oral CDAC designed to degrade mutant EGFR.

ClinicalTrials.gov ID: NCT06685718

A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This study targets patients with advanced colorectal, non-small cell lung, and gastric cancers expressing CEACAM5 by investigating the safety and preliminary efficacy of the investigational drug BMS-986490, with or without bevacizumab. Eligible participants must have previously progressed on standard therapies and have an ECOG performance status of 0 or 1.

ClinicalTrials.gov ID: NCT06730750

A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, focusing on gastric, GEJ, esophageal adenocarcinomas, and NSCLC, testing KK2269, a bispecific antibody targeting CD40 and EpCAM, alone and in combination with docetaxel to assess safety and tolerability.

ClinicalTrials.gov ID: NCT06266299

A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) As a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic Claudin-1 positive squamous solid tumors, including selected cases of squamous non-small cell lung cancer, head and neck, esophageal, or cutaneous squamous cell carcinoma that have become refractory or intolerant to standard therapies. It investigates ALE.P02, an antibody-drug conjugate targeting Claudin-1, aiming to deliver a tubulin inhibitor directly to CLDN1+ cancer cells.

ClinicalTrials.gov ID: NCT06747585

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets adults with advanced solid tumors, evaluating the safety and preliminary efficacy of the investigational antibody-drug conjugate BMS-986507 with either osimertinib, an EGFR tyrosine kinase inhibitor, or pembrolizumab, a PD-1 inhibitor, in patients with at least one measurable lesion and a good performance status.

ClinicalTrials.gov ID: NCT06618287

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.

ClinicalTrials.gov ID: NCT04969315

A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and anti-tumor activity of the investigational drug BMS-986488, alone or combined with adagrasib, cetuximab, or nivolumab, in adults with advanced malignant tumors, including specific cohorts with ccRCC, NSCLC (KRAS G12C mutation), ccOC, and CRC (KRAS G12C mutation).

ClinicalTrials.gov ID: NCT06764771

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates IAM1363, an oral, irreversible tyrosine kinase inhibitor targeting HER2 mutations, in adult patients with advanced cancers harboring HER2 alterations who have relapsed or are intolerant to previous therapies, including a subgroup with brain metastases.

ClinicalTrials.gov ID: NCT06253871

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express EGFR and have lost HLA-A*02 expression, including types such as CRC, NSCLC, HNSCC, TNBC, and RCC, and tests A2B395, a logic-gated Tmod™ CAR T-cell therapy designed to selectively target these tumor cells while sparing healthy cells. Participants receive a preconditioning lymphodepletion regimen followed by a single intravenous dose of A2B395.

ClinicalTrials.gov ID: NCT06682793